Stocks · News reference
Johnson & Johnson wins FDA accelerated approval for RYBREVANT FASPRO to treat recurrent or metastatic head and neck cancer.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The U.S. Food and Drug Administration has granted accelerated approval for RYBREVANT FASPRO as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma.
China's National Medical Products Administration (NMPA) has approved Johnson & Johnson's macitentan dispersible tablets for the treatment of pediatric pulmonary arterial hypertension.
Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, showing significant NEK7 degradation and reduction in cardiovascular disease markers with safety comparable to placebo. The company plans to initiate three Phase 2 studies in gout, coronary artery disease, and hidradenitis suppurativa. Additionally, Novartis initiated Phase 2 studies of partnered program MRT-6160 in Sjögren's disease and psoriatic arthritis, triggering $87.5 million in milestone payments. The company maintains a strong cash position of $582.6 million, expected to support operations into 2029.
Oxford BioDynamics (OBD) has entered into a commercial agreement with Johnson & Johnson for the use of its EpiSwitch® Orion platform.
T-Therapeutics closed a $133 million Series B funding round co-led by Advent Life Sciences and British Business Bank to advance clinical development of first-in-class TCR-CD3 bispecific therapies for cancer and autoimmune diseases. The company appointed Dr. Kirsty Crame as Chief Development Officer and plans to generate clinical proof-of-concept data for two lead programmes leveraging its proprietary OpTiMus platform.
Asgard Therapeutics published research in Immunity showing its in vivo cell reprogramming platform can reliably induce immunogenic tertiary lymphoid structures (imgTLSs) across seven tumor types. The technology reprograms tumor cells into dendritic cells (cDC1s), achieving 100% complete response rates in murine colon and breast cancer models compared to anti-PD1 monotherapy. New biomarker data for lead candidate AT-108 will be presented at SITC 2026, supporting advancement toward clinical development.